BiomX initiated with a Buy at Laidlaw

Laidlaw analyst Yale Jen initiated coverage of BiomX with a Buy rating and $2.50 price target. BiomX is a mid-clinical stage biotech company focusing on developing phage-based anti-infective therapies, the analyst tells investors in a research note. The firm says that with a “novel and clinical promising” phage-based therapeutics pipeline in place, the shares are undervalued at current levels.